Pharmaceutical News RSS Feed - Pharmaceutical News

Tolero Pharmaceuticals' Alvocidib gets Orphan Drug Designation for acute myeloid leukemia treatment

Tolero Pharmaceuticals' Alvocidib gets Orphan Drug Designation for acute myeloid leukemia treatment

Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the U.S. Food and Drug Administration has granted Orphan Drug designation for Alvocidib for the treatment of patients with acute myeloid leukemia (AML). [More]
HemoShear announces research collaboration with Medivir

HemoShear announces research collaboration with Medivir

HemoShear, LLC, the human disease biology company, today announced research collaboration with Medivir AB of Stockholm, Sweden, an emerging research-based pharmaceutical company focused on infectious diseases. [More]
Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals obtains orphan drug designation from EC for Soliris

Alexion Pharmaceuticals, Inc. today announced that the European Commission has granted an orphan drug designation (ODD) to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of graft rejection following solid organ transplantation. Graft rejection can cause severe injury to the transplanted organ and is a significant barrier to successful transplantation. [More]

Report recommends that medical insurers use prescription monitoring data to reduce opioid abuse

The Prescription Drug Monitoring Program Center of Excellence at Brandeis University has issued a ground-breaking report recommending that medical insurers use prescription monitoring data to reduce the overdoses, deaths and health care costs associated with abuse of opioids and other prescription drugs. [More]

TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

TWi Pharmaceuticals, Inc. today announced that it has entered into a settlement agreement with Endo Pharmaceuticals Inc., Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. to settle all outstanding patent litigation related to TWi's lidocaine topical patch 5% product. [More]
Global depression drugs market estimated to grow at 2.49% CAGR by 2018

Global depression drugs market estimated to grow at 2.49% CAGR by 2018

Research and Markets has announced the addition of the "Global Depression Drugs Market 2014-2018" report to their offering. [More]

7 in 10 Americans support mandated coverage of birth control medications, shows survey

Nearly 7 in 10 Americans support mandated coverage of birth control medications, according to a new national survey by researchers at the University of Michigan Health System. [More]
UT Southwestern researchers identify potential new treatment for depression

UT Southwestern researchers identify potential new treatment for depression

Researchers at UT Southwestern Medical Center are making breakthroughs that could benefit people suffering from depression. [More]

Drug used to treat hypertension prevents post-traumatic epilepsy in rodent model

Between 10 and 20 percent of all cases of epilepsy result from severe head injury, but a new drug promises to prevent post-traumatic seizures and may forestall further brain damage caused by seizures in those who already have epilepsy. [More]

New painkiller, with fewer side-effects, up for FDA approval

The drug, Moxduo, allows patients to take lower doses of other painkillers. Elsewhere, a Food and Drug Administration official talks about another painkiller, Zohydro. [More]

Bayer's Ciprofloxacin DPI receives FDA orphan drug designation for NCFB treatment

Bayer HealthCare today announced that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted orphan drug designation for its investigational Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) for the treatment of non-cystic fibrosis bronchiectasis (NCFB). [More]

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed. [More]
FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

FDA announces expanded approval of Arzerra in combination with chlorambucil for CLL treatment

The US Food and Drug Administration has announced the expanded approval of Arzerra (ofatumumab) in combination with chlorambucil for the first-line treatment of chronic lymphocytic leukemia (CLL). Arzerra was previously approved by the FDA in October 2009 for the treatment of CLL resistant to other forms of chemotherapy. Diplomat has access to dispense Arzerra. [More]
NBTY introduces Nature's Origin, a complete line of nutritional supplements

NBTY introduces Nature's Origin, a complete line of nutritional supplements

NBTY, Inc., a leading global manufacturer and distributor of high-quality vitamins and nutritional supplements, introduces Nature's Origin, its first complete line of vitamins, minerals and herbal supplements that are free from ingredients made with GMOs, preservatives, gluten and irradiation. [More]
Doctors must consider factors when administering combination vaccines, say researchers

Doctors must consider factors when administering combination vaccines, say researchers

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive option, according to a new study by University of Illinois researchers. [More]

Vietnam's pharmaceutical market records growth rate of nearly 17% in 2013

Decision Resources Group finds that Vietnam is currently one of the fastest growing pharmaceutical markets in Southeast Asia, recording a growth rate of nearly 17 percent and exceeding $3 billion in size in 2013. Increasing affluence, a rapidly aging population and the steady extension of public health insurance are among factors that are driving demand for prescription medicines. [More]
Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Penn study clarifies action of potential new class of pain relievers that may benefit and not hurt heart

Nonsteroidal antinflamatory drugs (NSAIDs) that block an enzyme called COX-2 relieve pain and inflammation but can cause heart attacks, stroke, heart failure, and even sudden cardiac death. [More]

Race to Yes campaign lauds Sarepta's plans to seek FDA approval for Duchenne treatment

The Race to Yes campaign today lauded drug maker Sarepta on its plans to move forward immediately to seek FDA approval of the first drug to successfully treat Duchenne muscular dystrophy, the world's leading genetic killer of children. [More]
New approach to handle people with dementia may help reduce use of antipsychotics drugs

New approach to handle people with dementia may help reduce use of antipsychotics drugs

A new approach to handling agitation, aggression and other unwanted behaviors by people with dementia may help reduce the use of antipsychotics and other psychiatric drugs in this population, and make life easier for them and their caregivers, a team of experts says. [More]
Study finds ginseng can help prevent, treat influenza and RSV infection

Study finds ginseng can help prevent, treat influenza and RSV infection

Ginseng can help treat and prevent influenza and respiratory syncytial virus (RSV), a respiratory virus that infects the lungs and breathing passages, according to research findings by a scientist in Georgia State University's new Institute for Biomedical Sciences. [More]